BASEL, Switzerland,
Feb. 10 /PRNewswire-FirstCall/ -
Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) Dr Claude Poulin is pleased to announce that on
February 9, MRES has received an
unsolicited offer for the purchase of all the outstanding shares at
$0.15 per share.
Management is currently conducting due diligence
and should be able to provide to its shareholders further details
by Tuesday February 15. The company
making the offer, with expertise similar to Neuro-Biotech, is
exclusively contracted by military forces to research and develop
new type of medications.
For more information on Neuro-Biotech Corp or to
contact a company representative, please visit:
www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Act of 1995. Certain statements in this press release
may contain words such as "anticipates," "believes," "could,"
"expects," "intends," "may," "projects," "targets" and other
similar language that is considered forward-looking statements.
These forward-looking statements are subject to certain risks and
uncertainties and persons reading this release are cautioned that
such statements are only predictions, and that the Company's actual
future results or performance may be materially different. The
Company disclaims any intention or obligation to update or revise
forward-looking information, whether as a result of new
information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
forward-looking statements.
SOURCE Neuro-Biotech Corp.
Copyright . 10 PR Newswire